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What is already known on this topic?
 ► Annual incidence of Rolandic epilepsy (RE) in 
a Swedish hospital- based study in 1974 was 
21/100 000 and 5/100 000 in an Icelandic 
population- based study in the 1990s.
 ► Attention deficit hyperactivity disorder has been 
reported in 31% of children with RE, cognitive 
problems in 22% and behavioural problems 
including pervasive developmental disorder in 
12%.
 ► There is debate whether drug treatment 
should be given; in the UK, carbamazepine and 
lamotrigine are recommended first- line, and 
sulthiame or valproate in other countries.
What this study adds?
 ► The incidence of RE in the UK has remained 
virtually unchanged since 2000; crude incidence 
in 2014 was 5/100 000/year and age, gender- 
adjusted incidence was 3.2/100 000/year.
 ► Population- based data confirmation that 
comorbidities occur in a proportion of children 
with RE; 12% were coded with any co- existing 
disorder and 6% with pervasive developmental 
disorder.
 ► Half of children with RE were prescribed 
anti- epileptic drugs with carbamazepine and 
valproate remaining the most frequently 
prescribed over the study period.
ABSTRACT
Objective To examine temporal trends in incidence of 
Rolandic epilepsy (RE), prevalence of comorbidities and 
antiepileptic drug (AED) prescribing patterns.
Design Retrospective cohort study.
Setting The UK.
Patients Children aged 0–16 years born 1994–2012 
were followed from birth until September 2017, transfer 
to another general practitioner practice or death or 
practice withdrawal from The Health Improvement 
Network (THIN), whichever occurred first.
Main outcome measures Incidence of RE, prevalence 
of comorbidity and AED prescribing patterns. Read codes 
for comorbidities and AEDs were adapted from other UK 
population- based epilepsy studies.
Results There were 379 children with first RE event 
recorded between 2000 and 2014 from active THIN 
practices with available mid- year population counts. 
Crude annual incidence across all years was 5.31/100 
000 (95% CI 4.81 to 5.88). There was no significant 
time trend in adjusted incidence rate ratios (aIRR) (0.99/
year, 95% CI 0.96 to 1.02). Males had higher aIRR (1.48, 
95% CI 1.20 to 1.82) as did children aged 6–8 and 9–11 
years compared with 4–5 years (aIRR 2.43, 95% CI 1.73 
to 3.40; aIRR 2.77, 95% CI 1.97 to 3.90, respectively). 
There was recorded comorbidity in 12% with 6% with a 
recorded diagnosis of pervasive developmental disorder. 
Half of children with RE had a record of being prescribed 
AEDs.
Conclusions UK incidence of RE has remained stable 
with crude incidence of 5/100 000/year. Carers and 
clinicians need to be aware that comorbidities may 
exist, particularly pervasive developmental disorders. 
Carbamazepine is consistently the most commonly 
prescribed AED for RE in the UK.
InTRODuCTIOn
Information on frequency, cause and natural 
history of Rolandic epilepsy (RE) is necessary to 
develop optimal treatment strategies. There are few 
published studies on the incidence of RE.1–4
Several factors influence incidence of epilepsy 
including socioeconomic status, gender, ethnicity, 
adaptation of regional or international guidelines 
in classification and management of epilepsy, avail-
ability of experts in epilepsy.5–7 As the presence 
and distribution of such factors can vary between 
countries, country- specific data on incidence of 
RE are most appropriate for resource allocation. 
Furthermore, country- specific incidence would best 
inform feasibility of recruitment targets for research 
studies. There are no contemporary UK studies on 
incidence of RE.
A retrospective, chart review, hospital- based study 
of 196 children with RE found high prevalence of 
comorbid cognitive and behavioural problems. 
Attention deficit hyperactivity disorder (ADHD) 
was found in 31%, 22% had specific cognitive 
problems and 11.7% had behavioural problems 
including anxiety, depression and pervasive devel-
opmental disorder (PDD).8 Other hospital- based 
studies have reported a higher prevalence of cogni-
tive problems in RE compared with control data.9 10 
A case- control study of 89 children with RE found 
they had higher anxiety and depression scores to 
controls.11 Hospital- based studies compared with 
population- based studies are more likely to produce 
biassed results. There are no population- based 
studies on comorbidities in RE.
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There has been a long- standing view RE does not need treat-
ment with antiepileptic drugs (AEDs).12 13 However, recent 
data suggesting positive treatment effects on cognitive and/
or behavioural comorbidities14 15 may influence whether to 
treat RE with AEDs. The potential negative cognitive and/or 
behavioural effects of AEDs are well recognised, with newer 
AEDs theoretically having fewer effects.16 In the UK, for chil-
dren who are given treatment, carbamazepine and lamotrigine 
are the recommended first- line AEDs. In Germany, Austria and 
Israel, it is sulthiame and in France it is valproate. The scientific 
evidence for these recommended AEDs is poor.17 Although there 
has been a UK survey on current treatment approaches,17 it is 
unclear whether prescribing patterns of AEDs in RE has changed 
over time. Given lack of evidence of optimum treatment of RE, 
well- designed trials, with realistic recruitment targets based on 
contemporary country- specific incidence estimates, are needed.
The aims of this study were to investigate temporal trends 
in incidence of RE, prevalence of comorbidities and AED 
prescribing patterns in the UK.
MeThODS
We carried out a retrospective cohort study using The Health 
Improvement Network (THIN), a large UK- wide clinical data-
base that prospectively captures Vision software electronic 
health record (EHR) data on prescriptions, diagnoses and symp-
toms in patients presenting to their general practitioner (GP).18 19 
THIN has been used to carry out a number of population- based 
studies.5 18 Ninety eight per cent of the UK population are 
registered with a GP who provides primary care services, refers 
patients for secondary care and shares care of patients seen in 
secondary care. In THIN, prescription data are automatically 
recorded each time a GP issues a prescription and coded using 
the UK Prescription Pricing Authority and classified according 
to the British National Formulary.18 Significant medical events 
are recorded by GPs and coded using the Read system. Data 
on contact with secondary care are entered from referrals and 
discharge letters. Demographic data on age, gender and post-
code derived Townsend scores of socioeconomic status are also 
usually available.18 19
As of January 2016, THIN contained pseudonymised 
primary care EHR from over 15 million patients, of whom over 
3.4 million are currently registered, representing almost 6% of 
the UK population, and is broadly representative of the UK in 
age, gender and social deprivation.19 Data are available from 
1990 onwards, with summarised medical information detailed 
prior to that. Childhood epilepsy diagnoses as a whole, rather 
than specific subtypes, in THIN have been previously validated.5
GP practice turnover is inevitable as some practices merge, or 
close, or switch to another software. Practices can also decline 
to continue contributing data to THIN. Within that structure, 
we had no scope to handle missing data or losses to follow- up. 
THIN practices are regularly assessed to ensure EHRs are of 
suitably high quality for research.18 19
Children aged 0–16 years born during 1994–2012 with a RE 
diagnosis (Read code F25y400) prior to September 2017 were 
included in the full cohort. Full EHR for all children qualifying 
for RE were available to the researchers. All participants were 
registered at (or within 6 months of) birth at one of the more 
than 550 THIN practices. All children were followed from birth 
until September 2017, transfer to another practice or death or 
withdrawal of the practice contributing data to THIN; whichever 
occurred first. Within the full cohort, we intended to examine a 
subcohort of children aged between 4 and 16 years in the period 
2000–2017 who were epilepsy- free at entry into the subco-
hort, to estimate the annual incidence of RE. However, there 
was a substantial increase in withdrawn/merged GP practices 
from 2015 onwards (online supplemental table 1). We therefore 
restricted analysis of annual incidence up to December 2014. 
The age range was chosen to cover the lower age RE usually 
starts, and upper age at which most would be seizure free.20
Codes used for identification of comorbidities and AEDs were 
adapted from population- based epilepsy studies2 5 21 22 and are 
provided as online supplemental material (online supplemental 
tables 2 and 3).
STATISTICAl AnAlySIS
We summarised over time number of practices contributing 
mid- year population counts and returning data satisfying THIN 
quality criteria. Mid- year population counts were summarised 
across practices.
For denominators, we examined number of children in every 
THIN practice irrespective of whether they identified cases 
of RE (ie, the base population) at the midpoint of each study 
year, broken down by: (i) age group in years 4–5; 6–8; 9–11; 
12–14, 15–16 years; (ii) gender; (iii) GP practice, (iv) quintiles 
of Townsend scores of socioeconomic deprivation. Townsend 
scores were not updated since 2011, and 7% of contributing 
practices did not contribute Townsend data. Also, data provided 
at the practice level were a mean of individual participants’ quar-
tile Townsend score which lacks interpretability and is much less 
sensitive to differences between practices. Therefore, we were 
unable to adjust for socioeconomic status.
Gender and age at onset of RE were summarised descriptively, 
as was presence of comorbidities. The proportion and 95% CIs 
of children with a record of any AED prescription after RE diag-
nosis were summarised over time.
Among the full cohort of children with RE who had at least 
10 years of follow- up from birth, the cumulative distribution of 
time to diagnosis of RE was estimated using Kaplan- Meier (KM) 
curves. We defined time to diagnosis as time from birth until first 
occurrence of RE diagnosis in GP records. Cumulative incidence 
of RE diagnosis by age 5 years and age 8years and 95% CIs were 
calculated. KM curves were plotted for four birth groups: 1994–
1996, 1997–1999, 2000–2002 and 2003–2006. To investigate 
changes over time in age of diagnosis, HR for each birth group 
(against the 2003–2006 reference group) and its 95% CIs were 
estimated from a Cox proportional hazards model. Significance 
of temporal changes was assessed by log- rank test for trend.
Crude incidence rates per 100 000 were summarised by year 
and age group. The number of children with a RE Read code 
was analysed using mixed effects Poisson regression including 
an offset for mid- year population. The model included poten-
tial confounders such as year, gender and age group as fixed 
effects and practice as a random effect. Year was modelled as 
categorical (3- year groups) or continuous variable: the contin-
uous version was centred on year 2000 and scaled if necessary. 
A linear year effect, cubic B- spline and categorical representa-
tion were compared using Akaike Information Criterion (AIC) 
and Bayesian Information Criterion (BIC) to determine which 
best modelled the relationship between year and incidence. 
Adjusted incidence rate and 95% CIs were calculated for each 
year adjusting for age, gender, year and GP practice. Adjusted 
incidence rate ratios (aIRR) and 95% CIs for model variables 
were calculated. As a sensitivity analysis, requirement to extend 
the model to a negative binomial or zero- inflated Poisson regres-
sion was investigated by comparing values of AIC and BIC across 
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Figure 1 Kaplan- Meier plot of time to first Rolandic epilepsy (RE) 
diagnosis by year of birth for children with a diagnosis of RE and at 
least 10 years of follow- up from birth.
Table 1 Age at diagnosis and gender, overall and by nation of residence for the incidence sample of 379, and for the full cohort of 516 children.
All england Scotland northern Ireland Wales
Full cohort
Number 516 365 83 22 46
Gender
  Male 325 (63%) 222 (61%) 61 (73%) * 27 (59%)
  Female 191 (37%) 143 (39%) 22 (27%) * 19 (41%)
Age at onset (years)
  Mean (SD) 8.6 (2.7) 8.5 (2.7) 8.4 (2.8) 9.7 (2.8) 9.3 (3.2)
  Min, Max 2, 18 2, 16 3, 14 3, 15 4, 18
Incidence sample
Number 379 304 38 11 26
Gender
  Male 232 (61%) 180 (59%) 28 (74%) * 15 (58%)
  Female 147 (39%) 124 (41%) 10 (26%) * 11 (42%)
Age at onset (years)
  Mean (SD) 9.0 (2.5) 8.9 (2.4) 9.1 (2.7) 10.3 (2.4) 9.6 (2.9)
  Min, Max 4, 16 4, 16 5, 14 7, 15 5, 16
Data are n, n (%), mean (SD) or min, max, where n is the number of children with Rolandic epilepsy (overall, and by nation).
*Not presented due to disclosure of small numbers.
models. All hypothesis tests were performed using a two- sided 
5% significance level. Analyses were carried out using SAS V.9.4 
(SAS Institute, Cary, North Carolina, USA).
ReSulTS
Online supplemental table 1 summarises mid- year population 
counts over time for practices. Withdrawn practices after 2014 
were similar sized to those which stayed in THIN, but most with-
drawals were in England (online supplemental table 4). Repre-
sentation of contributing ages of children by year is provided in 
online supplemental table 5.
There were 516 children with RE identified in the full cohort. 
Of those, 379 who had a first RE diagnosis recorded between 
2000 and 2014 and were from practices with available mid- year 
population counts were included as our final incidence analyses 
subcohort sample (online supplemental table 6). From the full 
cohort, the 317 children with at least 10- year follow- up were 
used to assess cumulative distribution of time to RE diagnosis 
(online supplemental table 6 and figure 1).
Table 1 summarises age at diagnosis and gender, overall and 
by nation of residence for the incidence sample of 379, and for 
the full cohort of 516 children. Age of RE diagnosis was similar 
across UK regions (mean age of 9 years).
Figure 1 illustrates time to RE diagnosis by year of birth, with 
no significant evolution in time to diagnosis (p=0.51). The 
proportion of children with RE diagnosed by 5 years was 14.2% 
(95% CI 10.2% to 18.5%) and by 8 years was 55% (95% CI 
49.5% to 60.4%).
Crude incidence rate over the study period was 5.31/100 000/
year (95% CI 4.81 to 5.88). Crude incidence rate by age group 
and year are provided in table 2A. In the Poisson regression 
model, a linear representation of year was clearly most appro-
priate, with lowest BIC (linear 4515; spline 4523; categorical 
4540). Age- adjusted and gender- adjusted incidence in 2014 was 
3.20/100 000/ year (95% CI 2.53 to 4.05). table 2B summarises 
aIRRs. Males showed significantly greater incidence (aIRR 1.48, 
95% CI 1.20 to 1.82) as did children aged 6–8 and 9–11 years 
compared with aged 4–5 years reference group (6–8: aIRR 2.43 
(95% CI 1.73 to 3.40); 9–11: aIRR 2.77 (95% CI 1.97 to 3.90)). 
There was no significant time trend in aIRR (p=0.38); Figure 2 
illustrates point estimate and 95% CI for adjusted incidence rate 
by year. Sensitivity analysis confirmed suitability of the Poisson 
regression model (AIC 4451; BIC 4515) compared with negative 
binomial (AIC 4450; BIC 4523) and zero- inflated Poisson (AIC 
4454; BIC 4583).
Table 3 provides data on comorbidities. Among the 379 inci-
dence RE children, 12% had a record of any co- existing disorder 
and 6% had a pervasive developmental disorder. Half of chil-
dren with RE were recorded as being prescribed AEDs; there 
was a higher proportion among those aged 6–11 years with 
prescriptions in more recent years (online supplemental figure 
1). The most frequent AEDs were carbamazepine (34%), sodium 
valproate (16%), lamotrigine (7%) and levetiracetam (5%). Over 
the study period, carbamazepine and valproate remained most 
frequently prescribed.
DISCuSSIOn
The main findings of this population- based study are1: incidence 
of RE in the UK remained virtually unchanged over the study 
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Table 2 Crude incidence rate of children with Rolandic epilepsy per 100,000 with 95% confidence intervals by age group and year, and adjusted 
incidence rate ratios (aIRR) with 95% confidence intervals.
A: Crude incidence rate of children with Rolandic epilepsy per 100 000 with 95% CIs by age group and year
year
Age in years
4–5 6–8 9–11 12–14 15–16
2000–2002 2.5 (1.1 to 6.1) 4.9 (2.6 to 9.1)
2003–2005 4.6 (2.6 to 8.1) 7.6 (5.3 to 10.8) 9.9 (6.8 to 14.4)
2006–2008 3.1 (1.6 to 6.0) 6.9 (4.8 to 9.8) 8.4 (6.1 to 11.4) 3.2 (1.7 to 5.9)
2009–2011 3.1 (1.7 to 5.7) 9.8 (7.3 to 13.0) 8.3 (6.1 to 11.3) 3.3 (2.1 to 5.4) 1.5 (0.6 to 3.9)
2012–2014 1.9 (0.9 to 3.9) 6.1 (4.3 to 8.6) 6.9 (4.9 to 9.8) 2.7 (1.6 to 4.7) 0.6 (0.2 to 2.4)
B. Adjusted incidence rate ratios (aIRR) and 95% CI
aIRR (95% CI) P value
Year 0.99 (0.96 to 1.02) 0.380
Age group (years)   
  4–5 Ref <0.0001
  6–8 2.43 (1.73 to 3.40)
  9–11 2.77 (1.97 to 3.90)
  12–14 1.06 (0.69 to 1.64)
  15–16 0.34 (0.14 to 0.80)
Sex   
  Female Ref 0.0002
  Male 1.48 (1.20 to 1.82)
Estimates are from aPoisson model including fixed effects of year, gender and age group, and arandom practice effect and an offset term for mid- year population estimates.
Figure 2 Adjusted incidence rate per 100 000 and 95% CI of year for 
Rolandic epilepsy in children over years 2000–2014.
Table 3 Record of a co- existing disorder in children with Rolandic 
epilepsy in the incidence sample (n=379)
n (%)
Any co- existing disorder 46 (12%)
Behavioural/emotional/social functioning/mental health <10*
Developmental (unspecified) 31 (8%)
Motor function/hyperkinetic/tic 13 (3%)
Pervasive developmental 21 (6%)
School problems 11 (3%)
Speech and language <10 (-%)
*Not presented due to disclosure of small numbers.
period with a crude rate in 2014 of 5/100 000/year (similar to 
the 1990s Icelandic studies) and a higher incidence among males 
and greatest incidence in children aged 6–11 years2; confir-
mation of the presence of comorbidities in RE, with a higher 
proportion of pervasive developmental disorders than reported 
in the general population3; ‘older’ type medications, in partic-
ular carbamazepine, are consistently preferred prescribed AEDs.
While there are studies that have examined temporal trend 
of childhood epilepsy as a whole (and show a decreasing inci-
dence),5 23 we are not aware of any other studies that have exam-
ined temporal trends of other specific benign childhood epilepsy 
syndromes. Our contemporary incidence rate of RE in the UK 
and factors that influence rate are similar to those reported in 
an Icelandic population- based study in 1998 that identified 38 
children3 but lower than the 21/100 000/year in a hospital- based 
Swedish study in 1975.1 All three have similar sociodemographic 
composition and ready access to paediatricians with expertise 
in epilepsy so difference in country- specific rates are likely 
to related to study design. With a crude incidence rate of 
5.31/100 000/year, applied to the 10 217 388 UK population 
of children aged 4–16 years (https://www. ons. gov. uk/ peop lepo 
pula tion andc ommunity/ popu lati onan dmig ration/ populationes-
timates/ datasets/ popu lati ones tima tesf oruk engl anda ndwa less cotl 
anda ndno rthe rnir eland), we estimate 542 new RE cases annually 
in the UK. This is higher than the 340 new RE cases estimated 
in 2012 by the UK- wide Epilepsy12 audit,1 24 but lower than 
the 751 estimated by a 2014 cross- sectional survey of UK paedi-
atricians with clinical responsibility for epilepsy.17 Discrepancy 
between our estimate and these two other UK studies may be 
related to differences in the study designs, low rate of syndromic 
diagnoses by reporting clinicians in Epilepsy12 audit, or multiple 
counts of patients who had shared care between a paediatrician 
and a tertiary paediatric neurologist in the cross- section survey. 
There is no financial incentive for UK GP practices to be more 
exacting in coding for epilepsy syndrome/type and it is possible 
that we missed RE cases recorded under another non- specific 
epilepsy code. However, equally there is no reason to believe 
that GPs would systematically not be more specific in coding 
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having received confirmation of a specific epilepsy syndrome 
from hospital specialists. Given identification of copy number 
variants at Xp22.31 as a risk factor for RE, we hypothesise 
higher incidence in males may be related to an X linked recessive 
genetic pre- disposition.4
RE was often previously referred to as benign RE as the seizures 
were often age- limited and were easily controlled. Our results 
provide further evidence that RE is more than seizures.14 25–27 
Consideration should be given to monitoring carefully for co- ex-
isting cognitive and/or behavioural problems particularly perva-
sive developmental disorders. Concerns that such comorbidities 
may not be well recorded in practices would suggest that our 
results are underestimates and true additional burden is more 
substantial.
Our finding that half of children with RE were prescribed 
AEDs by GPs is similar to the 60% of paediatricians who reported 
treatment in a recent cross- sectional survey.17 While the survey 
showed that carbamazepine was the preferred AED at one time- 
point, our study shows that it has consistently been the preferred 
AED over time. The lack of prescribing ‘newer’ AEDs (such as 
lamotrigine and levetiracetam) more often used after failure 
of ‘older’ AEDs (such as carbamazepine), probably reflects the 
natural history of seizures that are readily controlled. Given now 
recognised physical, cognitive and behavioural adverse effects in 
offspring,28 29 there are now UK- wide guidelines that restrict the 
use of valproate in females of potential childbearing age.28 At 
first glance it may seem surprising that valproate was the second 
most commonly prescribed AED, however these guidelines post-
date our study period. Futures studies may see valproate being 
prescribed much less in girls and an increase in alternatives of 
which lamotrigine and levetiracetam appear preferred.
lIMITATIOnS
THIN is representative of the UK population but care outside 
the GP setting is not fully captured. Studies using routine admin-
istrative datasets like THIN provide an opportunity to provide 
population- based data on research topics, obtain insight on real- 
life patient management and address clinically relevant questions 
more quickly and at lower cost than other study types. However, 
there may be data that are systematically missing and this limita-
tion needs to be borne in mind.
The risk of misdiagnosis of epilepsy is well known.30 We were 
unable to achieve the ideal of carrying out a direct validation 
of RE and comorbidities diagnoses and our results need to be 
considered in this context. However, medical diagnoses in THIN 
have high validity31–33 and high validity of epilepsy diagnoses, 
as whole rather than specific subtypes, in THIN has been previ-
ously reported. The high validity of diagnosis codes in THIN is 
likely related to the close relationship between THIN GP prac-
tices and hospital services. Although diagnosis of RE (as well 
as comorbidities) were extracted from GP records, the coded 
diagnoses are very likely to reflect clinical assessments by GPs as 
well as hospital specialists. RE has been a well- known epilepsy 
syndrome for decades with a well- established specific GP Read 
code. These factors, plus our finding of a stable incidence rate 
over time which is similar to that previously reported in another 
Western European country, plus not dissimilar estimated annual 
new RE cases compared with a national UK epilepsy audit and a 
UK cross- sectional study of RE17 24 give confidence that RE diag-
noses were true cases. THIN coding for other childhood epilepsy 
syndromes may not be the same as for RE. We postulate repre-
sentability of THIN as a source of scientific research of specific 
childhood epilepsy syndromes will be related to how familiar 
THIN database GPs are with individual syndromes and/or the 
availability of syndrome- specific Read codes. It can be debated 
that our observation of prescribing practices would be more 
accurately reflected as GPs frequently aid in long- term prescrip-
tion of AEDs. While it is possible that variation in coding over 
time and/or by GP practice could have impacted on our findings, 
any impact would probably have been minimal; had there been 
substantial variation, marked stepped changes would have been 
(and were not) observed.
COnCluSIOnS
The contemporary UK incidence of RE is 5/100 000/year and 
has remained virtually unchanged between 1997 and 2014; 
males and children aged 6–11 years have highest incidence. 
Carers and clinicians need to be aware that comorbidities may 
exist, particularly pervasive developmental disorders. Carbamaz-
epine is consistently the most commonly prescribed AED for RE 
in the UK. Designing potential UK clinical trials for RE should 
take these study findings into consideration. Finally, prospective 
studies with comprehensive enrolment of all epilepsy cases and 
detailed review by epileptologists could be useful to confirm our 
study findings.
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